Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
73.31
-1.03 (-1.39%)
Streaming Delayed Price
Updated: 10:14 AM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease
October 04, 2021
Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting
October 01, 2021
Kite Pharma, a Gilead Science Inc Company (NASDAQ: GILD), has submitted a supplemental marketing application to the FDA for Yescarta (axicabtagene ciloleucel...
Via
Benzinga
Exposures
Product Safety
3 Top Dividend Stocks Yielding More Than 4%
September 30, 2021
Make the most of your money with these generous income stocks.
Via
The Motley Fool
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
October 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...
Via
Benzinga
Exposures
Product Safety
Merck's COVID-19 Antiviral Pill Effective Against Variants, Lab Studies Show
September 29, 2021
Merck & Co Inc (NYSE: MRK) presented a study at a medical conference early Wednesday for its experimental COVID-19 antiviral candidate. What Happened: Laboratory...
Via
Benzinga
Exposures
COVID-19
GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option
September 28, 2021
The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for...
Via
Benzinga
Exposures
Product Safety
Gilead Scores Fifth Approval For Trodelvy In Triple-Negative Breast Cancer, This Time In Canada
September 28, 2021
Health Canada has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for previously treated breast cancer patients. The approval...
Via
Benzinga
Pfizer Begins Late-Stage Study To Test Effectiveness Of Oral Drug Against COVID-19 In Those Exposed To The Virus
September 28, 2021
Pfizer Inc (NYSE: PFE) says it has begun late-stage testing for an oral drug that can be taken by persons who are exposed to the virus that causes COVID-19. What Happened: The New...
Via
Benzinga
Exposures
COVID-19
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
September 27, 2021
A biotech working in lung and blood diseases, as well as cancer, could be acquired.
Via
Investor's Business Daily
Acceleron In Advanced $11B Buyout Talks: Bloomberg
September 27, 2021
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is...
Via
Benzinga
7 Members Of Congress Failed To Disclose Stock Transactions: Who Was Named, And What's Next?
September 24, 2021
The call for members of Congress to be banned from buying and selling stocks continues to heat up with a new report that seven members of the House of Representatives failed to...
Via
Benzinga
3 Relatively Safe Pharma Stocks You Can Buy Right Now
September 23, 2021
These stocks should be less volatile than many of the alternatives.
Via
The Motley Fool
EXCLUSIVE: NanoViricides' Remdesivir-Encapsulated COVID-19 Therapy Shows Encouraging Preclinical Safety Profile
September 21, 2021
NanoViricides Inc (NYSE: NNVC) has reported significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thus showing a potential pan-...
Via
Benzinga
Exposures
COVID-19
Barron's Latest Picks And Pans: Apple, Bitcoin, a Goldman Sachs ETF, Nike And More
September 18, 2021
This weekend's Barron's cover story examines the t...
Via
Benzinga
Baidu, Gilead Sciences And Nvidia Stocks Provide Plays For Both Bulls And Bears: Here's How
September 17, 2021
Baidu. Inc (NASDAQ:BIDU), Gilead Sciences, Inc
Via
Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
September 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...
Via
Benzinga
Look For The Q4 Biotech Bounce In Mid-Small Caps
September 17, 2021
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best...
Via
Talk Markets
Gilead Churns Out Additional Trodelvy Data
September 16, 2021
Gilead Sciences Inc (NASDAQ: GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic...
Via
Benzinga
This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And Gilead
September 06, 2021
Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused...
Via
Benzinga
COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?
August 31, 2021
Which subset of the COVID-19 healthcare market will outperform over the next year?
Via
The Motley Fool
Exposures
COVID-19
A Look Into Gilead Sciences Debt
August 31, 2021
Shares of Gilead Sciences (NASDAQ:GILD) rose by 7.09% in the past three months. Before we understand the importance of debt, let us look at how much debt Gilead Sciences...
Via
Benzinga
Galapagos' Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks
August 31, 2021
After 22 years at the helm of Galapagos NV (NASDAQ: GLPG), chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new...
Via
Benzinga
Could Moderna Take Down Gilead Sciences?
August 30, 2021
It's too early for a "yes" answer. But it's too premature for a "no" response as well.
Via
The Motley Fool
Gilead Wins Reversal of $1.2B Patent Loss to Bristol-Myers: Bloomberg
August 26, 2021
Gilead Sciences Inc (NASDAQ: GILD) persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Squibb & Co (NYSE: BMY) had won over immuno-...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Siemens' Fatty Liver Disease Blood Test Wins FDA De Novo Clearance
August 24, 2021
The FDA has granted clearance to a blood test from Siemens Healthineers (OTC: SMMNY) to provide an easier and potentially more accurate diagnostic alternative than an invasive...
Via
Benzinga
Exposures
Product Safety
Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
August 23, 2021
If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the...
Via
Talk Markets
Exposures
Product Safety
Why Fate Therapeutics Stock Is Sliding Today
August 20, 2021
The positive results the company announced after the bell yesterday didn't meet some lofty expectations.
Via
The Motley Fool
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
August 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Why NRx Pharmaceuticals Stock Jumped 11.8% Today
August 18, 2021
The company provided a positive update from a clinical study evaluating its COVID-19 therapy Zyesami.
Via
The Motley Fool
Exposures
COVID-19
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.